Objective: To study the clinical and immunological manifestations of antiphospholipid syndrome (APS) in the Japanese population by a single-centre registration. Methods: In this retrospective cohort study, 141 consecutive patients with APS, fulfilling the Sydney revised Sapporo criteria for definite APS, who visited our autoimmune clinic from 1988 to 2010, were recruited and followed up. All the patients were interviewed and underwent a general physical examination by qualified rheumatologists on the day of blood sampling. Results: The population comprised 119 woman and 22 men with a mean age at diagnosis of 44 years (range 9-79 years). Seventy patients (49.6%) had primary APS, and 71 (50.4%) had systemic lupus erythematosus. The prevalence of thrombosis was 85.8 per cent, arterial thrombosis was found in 93 patients (66.0%) and venous thrombosis was found in 46 patients (32.6%). The most common thrombosis was cerebral infarction [86/141 (61.0%)] followed by deep vein thrombosis [33/141 (23.4%)]. Among 70 pregnant women, 45 (64.3%) had obstetric complications. Lupus anticoagulant was detected in 116 patients (82.3%), anticardiolipin antibodies in 83 (58.9%), anti-b2 glycoprotein I antibodies in 73 (51.8%) and phosphatidylserine-dependent antiprothrombin antibodies in 98 (69.5%). Conclusion: High prevalence of arterial thrombosis was noted in Japanese patients with APS. The profile of heterogeneous and complex clinical manifestations was substantiated in Japanese patients with APS. Lupus (2012) 21, 1506-1514.
Introduction
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by widespread arterial and venous thrombosis together with adverse pregnancy history, and is associated with the persistent presence of antiphospholipid antibodies (aPLs). 1 aPLs are a heterogenous group of circulating immunoglobulins which are usually detected by their binding to immobilized anionic phospholipids in solid-phase enzyme-linked immunosorbent assays (ELISAs), termed anticardiolipin antibodies (aCLs) 2 or by their ability to prolong the clotting time of phospholipid-dependent coagulation assays, namely lupus anticoagulant (LA). 3 Although the original concept of aPL considers that those antibodies are directed against anionic phospholipids, evidence shows that the antigenic specificities of aPL include phospholipid-bound plasma proteins such as b2 glycoprotein I (b2GPI) [4] [5] [6] or prothrombin. 7 Since the first description of APS in 1983, 8 the range of features associated with aPLs has considerably increased. APS may present with heterogeneous clinical symptoms and laboratory manifestations. In addition, APS is relatively rare and therefore, it has been difficult to carry out epidemiological studies. Additional factors such as the diversity in the definition of the variables and the lack of standardization of laboratory tests may influence the results of those studies.
In 1999, the preliminary classification criteria for APS (Sapporo criteria) were published. 9 Based on those criteria, Cervera et al. 10 reported the clinical and immunological manifestations of 1000 European patients with APS. This multicentre international study included patients from 13 countries and provides different patterns of disease expression in a large cohort of patients with APS.
Since the publication of Sapporo criteria, new clinical, laboratory and experimental insights on APS were addressed. A preconference workshop, preceding the 11th International Congress on aPL considered revisions to the Sapporo criteria, and the Sydney revised Sapporo criteria for definite APS were proposed. 11 The revised criteria provide definitions of the features in patients with APS that were not included in the Sapporo criteria. Also, in the revised criteria IgG/IgM anti-b2GPI antibodies (ab2GPI) are listed together with aCL and LA to categorize APS.
The aim of this study was to analyse the clinical and immunological manifestations of APS, according to the Sydney revised Sapporo criteria for APS classification, in a cohort of Japanese patients recruited in a single centre. All the patients were followed up; the prevalence of APS manifestations and the profile of aPL during the study period were evaluated.
Patients and methods

Patients
This study is a retrospective cohort study of Japanese patients with APS. The study was conducted in a single centre at Hokkaido University Hospital in Sapporo.
The autoimmune disease database of the autoimmune outpatient clinic was queried for diagnosis of APS registered between 1 January 1988 and 31 December 2010. A retrospective review of the clinical charts of the patients with APS was performed, and the diagnosis of APS according to the Sydney revised Sapporo criteria for definite APS 11 verified by the authors. The historical profile of thrombotic manifestations, obstetric complications and laboratory findings from each visit was obtained by the authors using medical records. The coexistence of systemic lupus erythematosus (SLE) was diagnosed according to the American College of Rheumatology (ACR) revised criteria. 12 On the first visit, all the patients were interviewed and underwent a general physical examination by a qualified rheumatologist. Serum and plasma samples from each patient were collected for initial laboratories studies. The patient's clinical examination and laboratory findings on the follow-up visits to the outpatient clinic were obtained from the medical records. The study was conducted in accordance with the Declaration of Helsinki and the principles of good clinical practice.
Clinical manifestations
The presence of arterial thrombosis was confirmed by brain magnetic resonance imaging (MRI), angiography and computed tomography scan. Ischaemic heart disease including myocardial infarction and angina was confirmed by electrocardiographic changes, increased cardiac enzymes and coronary angiography. Venous thrombosis was confirmed by radio isotope (RI) venography, Doppler ultrasound, flebography, lung perfusion scintigraphy or retinal fluorescence. Pregnancy morbidity was defined according to the Sydney revised Sapporo criteria. 11 Information about the following risk factors for arterial thrombosis was obtained from the medical records. Current cigarette smoking was defined as smoking. Patients were classified as having hypertension if they used antihypertensive medication, had a systolic blood pressure !140 mmHg or had a diastolic blood pressure !90 mmHg. Dyslipidaemia was defined as the use of lipid-lowering agents or an elevated serum low-density lipoprotein concentration >140 mg/dl. Diabetes was defined as the use of antidiabetic medication or an increased level of haemoglobin A1C >6.5 per cent. Steroid treatment was defined as the use of any oral or intravenous corticosteroid therapy. The use of other drugs including anti-platelet agents, statins and anticoagulant therapy was also recorded.
Laboratory investigations
Venous blood was collected in tubes containing 1/ 10 volume of 0.105 M sodium citrate and was centrifuged immediately at 4 C. Plasma samples were depleted of platelets by filtration then stored at À80 C until they were used.
The presence of aPL was evaluated in all patients at the first visit and at least 12 weeks apart. aCLs (IgG and IgM) were assayed according to the standard ELISA. 13 For the detection of LA, clotting tests were performed using a semiautomated haemostasis analyser (STart 4; Diagnostica Stago, Asnie`res sur Seine, France) and the previous version of the guidelines recommended by the Subcommittee on LA/aPL of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis (SSC-ISTH) were followed. 3 For measurement of the activated partial thromboplastin time (aPTT), a sensitive reagent with low phospholipid concentration (test PTT-LA; Diagnostica Stago) was used for a screening and mixing test, and the results were confirmed with the use of a Staclot LA kit (Diagnostica Stago). The dilute Russell's viper venom time (dRVVT) was screened and confirmed by use of a Gradipore LA test (Sydney New South Wales, Australia). The kaolin clotting time (KCT) was measured using a kaolin solution (Dade Behring, Liederbach, Germany) with the standard protocol. The cut-off levels for the LA tests were previously established as >99th percentile of 40 healthy subjects, as our routine laboratory assays.
IgG and IgM ab2GPI were determined by ELISA as reported previously. 14 Briefly, irradiated microtitre plates were coated with 4 mg/ml of purified b2GPI (Yamasa Corp. Tokyo, Japan) in phosphate-buffered saline (PBS) at 4 C and washed with PBS. Wells were blocked with 3% gelatine (BDH Chemicals Ltd, Poole), washed with PBS 0.05% Tween 20 (Sigma Chemical Co., St Louis, MO, USA) (PBS-Tween) and 50 ml of serum 1:50 diluted with PBS containing 1% bovine serum albumin (Sigma) (PBS-1% BSA) were added in duplicate. Plates were incubated for 1 hour at room temperature, washed and the appropriate dilution of alkaline phosphatase (ALP)-conjugated goat anti-human IgG and IgM (Sigma) in PBS-1% BSA was added. After 1 hour of incubation at room temperature and four washes, 100 ml/well of 1 mg/ml pnitrophenylphosphate disodium (Sigma) in 1 M diethanolamine buffer (pH 9.8) was added. Following colour development, optical density (OD) at 405 nm was measured by a Multiskan ascent plate reader Multiscan Ascent plate reader (Thermo Electron Corporation, Waltham, Massachusetts, USA). Normal ranges of IgG and IgM ab2GPI with cut-off values of 99th percentile were established previously using 132 healthy controls.
IgG and IgM phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) were evaluated by an in-house ELISA using the phosphatidylserine/prothrombin complex as antigen. 15 Nonirradiated microtitre plates (Sumilon type S, Sumitomo Bakelite, Tokyo, Japan) were coated with 50 mg/ml of phosphatidylserine (Sigma), and dried overnight at 4 C. Wells were blocked with 150 ml of Tris-buffered saline (TBS) containing 1% fatty-acid free BSA and 5 mM CaCl 2 (BSA-Ca). After three washes in TBS 0.05% Tween 20 with 5 mM CaCl 2 (TBS-Tween-Ca), 50 ml of 10 mg/ ml human prothrombin (Diagnostica Stago, Asnieres, France) in BSA-Ca was added to half of the wells in the plates and the same volume PS of BSA-Ca alone to the other half. After 1 hour incubation at 37 C, plates were washed and 50 ml of serum diluted in BSA-Ca in 1:100 was added in duplicate. Plates were incubated for 1 hour at room temperature, followed by ALP-conjugated goat anti-human IgG or IgM and substrate. The aPS/PT titre of each sample was derived from the standard curve according to dilutions of the positive control. Normal ranges of IgG and IgM aPS/ PT with cut-off values of 99th percentile were established previously using 132 healthy controls.
Statistical analysis
Statistical evaluation was carried out by Fisher's exact test or chi-square test as appropriate. Pvalues <0.05 were considered significant.
Patient characteristics and risk factors were entered into a multivariate logistic regression model to identify variables that independently predicted the development of arterial thrombosis. Calculations were made using the statistical software package SPSS statistics (version 18.0).
Results
Patient features
A total of 141 consecutive patients with the diagnosis of APS were recruited.
The cohort comprised 119 females and 22 males. Table 1 shows clinical and demographic characteristics in our cohort. Mean age at disease onset was 41.2 years (range 9-79 years) and mean age at end of follow-up was 48.6 years (range 18-87 years). Median follow-up period was 7 years (range 0-22 years). Fifty per cent of the patients with APS had SLE. The number of patients with hypertension or taking anticoagulation/steroid therapy was higher in patients with SLE compared with those with primary APS. Eight patients with primary APS were on steroid therapy due to arthritis.
Thrombotic events
Thrombosis was found in 121 patients (85.8%), arterial thrombosis in 93 and venous thrombosis in 46 (66% and 32.6%, respectively) ( Table 2) . Among patients with arterial thrombosis, the most common manifestation was cerebral infarction observed in 86 patients (61.0%).
Other arterial thrombotic events are summarized in Table 2 . Ischaemic heart disease, arterial ischaemia in legs, mesenteric artery occlusion, splenic infarction and renal infarction were documented.
The most common thrombotic event in the venous territory was deep vein thrombosis found in 33 (23.4%) patients, followed by pulmonary embolism in 14 (9.9%) patients ( Table 2) .
During the study period, 34 recurrences of the thrombotic events were observed in 31 patients. Among them, 10 patients (32%) were on anticoagulation/anti-platelet combination therapy, nine patients (29.0%) on anticoagulation only and 12 patients (38.7%) on anti-platelet only. Twenty one out of 31 patients (67.7%) were taking steroid treatment and eight (25.8%) statins. Patients on warfarin/anti-platelet combination therapy had a high rate of recurrence compared with those receiving either anticoagulation or anti-platelet. This finding could be explained because patients with high risk of recurrence were those who received more aggressive treatment with combination therapy. Recurrent arterial thrombosis was found in 22 patients (15.6%) and recurrent venous thrombosis in nine (6.4%). In twenty-four patients (77.4%) the thrombotic event recurred in the same vascular territory (arterial event recurred in an arterial location and venous event in a venous vessel). Only three patients with arterial thrombosis at disease onset developed a venous thrombotic event during follow-up, and four patients with venous thrombosis had a new thrombotic event in the arterial circulation.
Obstetric complications
Our cohort includes 70 women who became pregnant during the study period.
Forty-five out of 70 pregnant females (64.3%) had obstetric complications defined in the Sydney revised Sapporo criteria for pregnancy morbidity. 11 One or more incidents of fetal loss at or beyond the tenth week of gestation was found in 32 females (45.7%), one or more premature births before the thirty-fourth week of gestation in 12 females (17.1%) and three or more unexplained abortions before the tenth week of gestation in 10 females (14.3%) ( Table 2) .
The total number of pregnancies that occurred in 70 pregnant females in our cohort during the study period was 169. We documented 104 pregnancy losses; 54 (32.0%) were early fetal loss that occurred before the tenth week of gestation and 50 (29.6%) were deaths of fetus at or beyond the tenth week of gestation. Fifteen pregnancies (8.9%) resulted in premature births of a neonate before the thirty-fourth week of gestation and 50 (29.6%) in full-term births ( Table 2) .
Among 169 pregnancies observed in our cohort, 119 (70.4%) presented with some of the APSrelated pregnancy complications described above. Obstetric problems were observed in 45 pregnant females. However, in 25 females, a total of 50 pregnancies developed without any APS-related obstetric problems.
Antiphospholipid antibody profile
Antiphospholipid antibodies were assayed in all the patients at the first visit and at least 12 weeks apart. Several other evaluations of aPL were performed in the routine visits during the study period.
The prevalence of each evaluated aPL is presented in Table 3 . LA was the most prevalent aPL detected in 116 patients (82.3%). aCL were found in 83 patients (58.9%), ab2GPI in 73 (51.8%) and aPS/PT in 98 (69.5%). There was no correlation between aPL profile and any particular APS manifestations, such as thrombosis or obstetric events. The aPL profile in the cohort is shown in Figure 1 . Twenty-six patients (18.4%) had either LA, aCL or ab2GPI as the sole aPL during the study period. The presence of LA in conjunction with IgG/IgM aCL, IgG/IgM ab2GPI and IgG/IgM aPS/PT was detected in 45 patients (31.9%). The combination most frequently found was the presence of LA in conjunction with IgG/IgM aPS/PT that was detected in 28 patients (19.9%).
Comparison of clinical characteristics between patients with or without associated thrombotic risk factors
Additional risk factors for thrombosis were defined according to the classification proposed in the Sydney revised criteria for definite APS. 11 The presence of thrombosis, arterial thrombosis and stroke was more prevalent in the group of patients with additional risk factors for thrombosis, odds ratio (OR), 95% confidence interval [ (Table 4 ).
Risk factors of arterial thrombosis
Patients with APS were grouped according to the presence or absence of arterial thrombosis.
The presence of the above-mentioned risk factors for arterial thrombosis is shown in Table 5 . Age and hypertension represent a risk for having arterial thrombosis in our Japanese APS cohort. The relative risk approximated by OR, 95% CI was 1.82, [1.30-2.54] and 3.26 [1. 16-9.14] for age by decade and hypertension, respectively.
Discussion
In this observational study, we retrospectively analysed the clinical and immunological characteristics of APS in a large cohort of Japanese patients and observed a high incidence of arterial thrombotic events. This is the first large Asian cohort of APS analysed. The study design enables a detailed and accurate collection of data in a homogenous population.
APS is a heterogeneous autoimmune disease with several patterns of disease expression as reported in a Caucasoid cohort of patients with APS. 10 This cohort was established in the Europhospholipid project with a multicentre and prospective design and comprised 1000 patients. The multicentre design of the study allowed the collection of a large population of patients with APS, but has several limitations due to the diversity of clinicians involved in the diagnosis and management The presence of antibodies was defined as described in the Patients and Methods section. To be considered positive, antibodies were present on two or more occasions in plasma samples at least 2 weeks apart. We present a single-centre study in which all the patients were recruited in the same autoimmune disease clinic and with all the aPL determination performed in the same laboratory. Our cohort showed a high incidence of arterial thrombotic events. Especially elevated was the rate of cerebral infarction in the Japanese cohort, 61.0 per cent compared with 19.8 per cent in the European cohort. 10 There was no correlation between aPL profile and arterial thrombosis in our cohort. In contrast, there was correlation between the presence of additional thrombotic risk factor and arterial thrombosis by univariate analysis ( Table 4 ). As a result of multivariate analysis, hypertension appeared as a risk for arterial thrombosis (Table  5 ). Ruffatti et al. reported hypertension as a risk for the first thrombotic event in aPL carriers by retrospective and prospective cohort studies. 16, 17 Previous studies with smaller numbers of patients have also shown the association between hypertension and arterial thrombosis. 18, 19 Our data in the Japanese cohort support those previous observations in European and American patients, therefore hypertension would be one of the most important risks for having arterial diseases in patients with aPL beyond races/populations. Blood pressure values are known to be relatively higher in Japanese than in other developed country populations, 20 and might represent one of the plausible explanations of why Japanese patients with APS are more prone to have stroke than European patients with APS. The prevalence of deep vein thrombosis in the Japanese population (23.4%) was, in contrast, lower than that in the European population (38.9%). 10 The prevalence of deep vein thrombosis is also known to be lower in Japanese than in other developed country populations. 21, 22 Considering the epidemiological characteristic that the Japanese population is more prevalent in arterial thrombosis and less in venous vascular events, it is likely that the genetic and/or environmental background affects the prevalence of thrombotic events as well in patients with aPL. We observed a similar incidence between early and late fetal loss in the cumulative obstetric manifestations in 169 pregnancies (32% had early fetal loss and 29.6% late fetal loss). The high incidence of late fetal loss in our cohort could be explained in part because our patients were recruited at Hokkaido University Hospital, a referral centre for risk pregnancy patients for the whole Hokkaido area. In addition, we observed a high rate of late fetal loss recurrence among 50 patients with late fetal loss. Eleven (22%) patients with first late fetal loss had recurrent episodes of late fetal loss varying from two to six times.
Taken together, our observation would support the argument that aPL represents a risk of thrombotic events and/or pregnancy morbidity, rather than as a diagnostic tool. [23] [24] [25] [26] [27] Regarding aPL profile, there is a great variety in the methodology for antibody testing among different laboratories which make it difficult to conduct a comparison of the results. In the Sydney revised Sapporo criteria, both LA and aCL (IgG and IgM) were maintained as laboratory criteria and ab2GPI (IgG and IgM) added. More importantly, the cut-off setting was defined by non-parametric 99th percentile of healthy population in aCL and ab2GPI ELISAs, making the results of the prevalence more comparable among the laboratories. Prevalence of aCL (IgG or IgM) and ab2GPI (IgG or M) in the Japanese APS cohort was 58.9% and 51.8%, respectively. aCL was less prevalent in our series than in the European cohort (88%) and these variations may be explained, in part, by the methodological or cutoff setting differences among the laboratories.
LA tests used for screening in routine laboratory practice display large differences in sensitivity and responsiveness, according to the reagent, the automated and the procedure employed. 28 Therefore, the SSC-ISTH recommends to use at least two different screening tests. 3 In our study we tested LA using three procedures and found LA in 82.3 per cent of patients, and in 14 patients (9.9%) LA was the only aPL detected. It is already recognized that the presence of ab2GPI is correlated with thrombosis and pregnancy complications, [29] [30] [31] [32] although there are still some controversial reports denying these associations. The Sydney revised Sapporo criteria for APS take into account the limitations of ab2GPI as a criterion mainly because of methodological differences and lack of standardization which make it difficult to interpret the results. We found a prevalence of ab2GPI of 51.8 per cent, including four (2.8%) patients in the absence of LA and aCL, with the method being performed for 17 years in our laboratory. Antibodies reacting with b2GPI are detected in some patients in the absence of aCL. There are, at least two possible explanations for those findings. First, the target epitopes located on b2GPI for ab2GPI binding are cryptic when b2GPI is combined with cardiolipin in the solidphase assay. These types of ab2GPI in the absence of aCL have been detected in children with atopic dermatitis. 33 The second possibility is related to the cut-off setting. The aCL ELISA detects a lot of non-specific low-affinity antibodies in an apparently healthy population leading to the setting of a higher cut-off level (99th percentile) compared with ab2GPI cut-off. Therefore, borderline positive ab2GPI turned negative in the aCL ELISA assay.
Antiprothrombin antibodies attracted the interest of many researchers in the APS field as responsible for the LA activity. 7, 34 It is recognized that antiprothrombin antibodies presumably recognize an epitope exposed upon calcium-mediated binding of human prothrombin to phospholipids. 34 Antiprothrombin antibodies are more efficiently detected when prothrombin is bound to phosphatidylserine coated onto ELISA plates in the presence of calcium, the aPS/PT ELISA. 35 The clinical significance of antiprothrombin antibodies has not yet been elucidated, 36 but aPS/PT showed higher correlation with venous and arterial thrombosis, and LA. 15 As well as b2GPI-dependent aCL, aPS/PT had high sensitivity and specificity for the diagnosis of APS and are considered useful tools for the diagnosis of APS. 37 According to our previous observation, we investigated the prevalence of antiprothrombin antibodies by the aPS/PT ELISA. In our cohort, the prevalence of aPS/PT was higher than that of aCL (69.5% vs 58.9%) supporting the possibility of its usefulness as a marker of APS.
In conclusion, this single-centre Japanese APS cohort shows the analysis of the clinical and immunological feature of Japanese patients with APS. The characteristic of clinical manifestations in Japanese APS would represent the profile of the general Japanese population, therefore it is likely that not only aPL but a number of genetic/ environmental factors play roles to develop the syndrome.
